772311-98-5

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE is utilized as a chemical building block for the synthesis of various compounds in the pharmaceutical industry. Its unique structure allows it to be a key component in the creation of new drugs, potentially contributing to the development of novel therapeutic agents.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE is employed as a reagent or intermediate for the preparation of complex organic molecules. Its presence in the synthesis process can influence the properties of the final product, such as stability, solubility, and biological activity.
Used in Medicinal Chemistry:
4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE is used as a structural element in medicinal chemistry to design and optimize drug candidates. Its incorporation into molecular frameworks can enhance the pharmacokinetic and pharmacodynamic profiles of potential drugs, improving their efficacy and safety.
Used in Biochemical Research:
In biochemical research, 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE may be used as a probe or a modifier to study the interactions of biological molecules. Its chemical properties can be leveraged to investigate enzyme mechanisms, receptor binding, or other biological processes.

InChI:InChI=1/C11H13N3/c1-9-13-6-7-14(9)8-10-2-4-11(12)5-3-10/h2-7H,8,12H2,1H3

Upstream product

• 56643-86-8 4-(2-Methylimidazol-1-ylmethyl)nitrobenzene 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Downstream Products

• 125665-48-7 N-[4-(2-Methyl-imidazol-1-ylmethyl)-phenyl]-phthalamic acid 
• 1147015-38-0 1-isopropyl-7-((2-(4-((2-methyl-1H-imidazol-1-yl)methyl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)ethynyl)-1H-indole-3-carbonitrile 
• 1142947-77-0 1-(4-((2-methyl-1H-imidazol-1-yl)methyl)phenyl)guanidine 
• 1147015-37-9 ⁽⁰⁸¹⁾C₀₇₅₀₆ 
• 1147015-36-8 2-[4-(2-methyl-imidazol-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-ol 
• 1143571-99-6 (E)-tert-butyl (tert-butoxycarbonylamino)(4-((2-methyl-1H-imidazol-1-yl)methyl)phenylamino)methylenecarbamate 

Relevant academic research and scientific papers

Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML

Bruton's tyrosine kinase (BTK) is a member of the Tec kinase family and plays a key role in the modulation of the B-cell receptor (BCR)-mediated signaling pathway. Inhibition of BTK has been proven to be an effective therapeutic approach for various hemat

Azolo pyrimidine derivative, pharmaceutical composition thereof and application of azolopyrimidine derivative in tumor resistance

The invention discloses an azolopyrimidine derivative, a pharmaceutical composition thereof and an application of the azolopyrimidine derivative in tumor resistance, and relates to the field of medicines and chemical engineering. The azolopyrimidine deriv

The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives

A new class of potent antihypertensives has been discovered that exert their effect through blockade of the angiotensin II (AII) receptor.Most AII antagonists reported so far are peptide mimics of the endogenous vasoconstrictor octapeptide angiotensin II.The compounds of this paper are nonpeptides and therefore constitute a new class of potent AII receptor antagonists.Based on the overlap of a conformation of AII with literature lead 3, a hypothesis was developed suggesting the need for an additional acidic functionality to increase the lead's potency.The substitution of an additional carboxylic acid resulted in a 10-fold increase in binding affinity observed for diacid 4.The binding affinities for subsequent compounds were eventually increased 1000-fold over that of the literature leads through a systematic SAR study.Thus the AII receptor binding affinity 50 (μM)> of 15 μM for literature lead 1, for example, was increased to 0.018 and 0.012 μM for compounds 33 and 53.A structure-affinity relationship has been found requiring the presence of four key elements for good activity: (1) an additional phenyl ring at the N-benzyl para position of the benzylimidazole nucleus, (2) an acidic functionality at the ortho position of the terminal aromatic ring, (3) a lipophilic side chain at the imidazole 2-position of three to five carbon atoms in length, and (4) a group at the imidazole 5-position capable of hydrogen bonding.The synthesis as well as the pharmacological activity of the compounds in this new series of AII receptor antagonists are presented.